Reshaping the HIV treatment and prevention landscape
Competitive sales ambition
Pipeline productivity and commercial excellence
Illustrative
Vaccines
Specialty Medicines
General Medicines
More than
5% CAGR
+ Shingrix
+ Meningitis
+ Dovato
+ Cabenuva
+ Zejula
+ Blenrep
+ RSV
+ Men ABCWY
+ Cab PrEP
+ Zejula
+ Blenrep
+ Jemperli
+ depemokimab ('294)
+ Jemperli*
+ Benlysta
+ otilimab
+ Nucala
+ daprodustat
2021
+ Trelegy
+ gepotidacin
Marketed assets
Late-stage Pipeline
2026
- dolutegravir
-
Trelegy
Anoro
More than
£33bn
gsk
+ RSV
+ Men ABCWY
+ Blenrep
+ Zejula
+ HBV ASO ('836)
+ depemokimab ('294)
+ otilimab
+ daprodustat
+ gepotidacin
+ Next gen Flu
+ CD226 axis
+ LA HIV combos
+ Cell therapies
+ MAT2A
+ Other
+ BD
LoE + base decline
Growth drivers
2031
Note: Bars are not at scale. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of
Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. 2021-26 CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted
and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the
above. Assets highlighted reflect major contributions to growth in period shown.
*Tesaro asset
Early pipeline+ BD
103View entire presentation